Decernotinib
Decernotinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against tyrosine-protein kinase JAK3. In addition, it is known to target tyrosine-protein kinase JAK1 and tyrosine-protein kinase JAK2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | Decernotinib |
| INN | decernotinib |
| Description | Decernotinib is an inhibitor of Janus kinase 3 (JAK3) discovered through a process of inhouse screening of a chemical compound library. Decernotinib also had the name VX-509 in development phase. It is an experimental drug with high selectivity for JAK3, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). It is being studied in clinical trials at Vertex.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 944842-54-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3039513 |
| ChEBI ID | — |
| PubChem CID | 59422203 |
| DrugBank | — |
| UNII ID | MZK2GP0RHK (ChemIDplus, GSRS) |
Target
Agency Approved
JAK3
JAK3
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use